Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002 - implications for vaccine serotype coverage

Authors

  • Michael Watson NSW Pneumococcal Reference Laboratory, Department of Microbiology, Children's Hospital at Westmead, Locked Bag 4001, Westmead NSW 2145
  • K Bayley Department of Microbiology, Women's and Children's Health Service, Western Australia
  • Jan M Bell Department of Microbiology and Infectious Diseases, Adelaide Women's and Children's Hospital, New South Wales
  • Gwendolyn L Gilbert Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales
  • Geoff Hogg Microbiological Diagnostic Unit, Public Health Laboratory, Microbiology and Immunology Department, University of Melbourne, Victoria
  • Anthony D Keil Department of Microbiology, Women's and Children's Health Service, Western Australia
  • Vicki Krause Centre for Disease Control, Department of Health and Community Services, Northern Territory
  • Denise Murphy Pneumococcal Reference Laboratory, Queensland Health Scientific Services, Queensland
  • Paul Roche Surveillance and Epidemiology Section, Australia Government Department of Health and Ageing, Canberra, Australian Capital Territory
  • Helen V Smith Pneumococcal Reference Laboratory, Queensland Health Scientific Services, Queensland
  • Marriane G Stewart New South Wales Pneumococcal Reference Laboratory, Department of Microbiology, Children's Hospital at Westmead, New South Wales
  • Joanne Stylianopoulos Microbiological Diagnostic Unit, Public Health Laboratory, Microbiology and Immunology Department, University of Melbourne, Victoria
  • John Turnidge Department of Microbiology and Infectious Diseases, Adelaide Women's and Children's Hospital, New South Wales

DOI:

https://doi.org/10.33321/cdi.2003.27.76

Keywords:

Streptococcus pneumoniae, disease surveillance, pneumococcal disease

Abstract

This paper reports the results of comprehensive laboratory surveillance of invasive pneumococcal disease (IPD) in Australia during 2001 and 2002. The 7-valent conjugate pneumococcal vaccine was introduced for high risk paediatric groups, including Indigenous children, in late 2001. Of 1,355 isolates from non-Indigenous children, 86 per cent belonged to serotypes and 93 per cent to serogroups represented in the 7-valent pneumococcal conjugate vaccine. Thirteen per cent and 24 per cent of isolates had reduced susceptibility to penicillin and erythromycin, respectively and of these, more than 99 per cent belonged to serogroups represented in the 7-valent vaccine. Of the 1,504 isolates from non-Indigenous adults, 96 per cent belonged to serotypes included in the 23-valent polysaccharide vaccine; 14 per cent and 15 per cent had reduced susceptibility to penicillin and erythromycin, respectively and more than 95 per cent of these belonged to serotypes included in the 7-valent conjugate vaccine. In Western Australia and the Northern Territory (the only states for which Indigenous status was consistently available), there were 29 cases of IPD in Indigenous children, of which 21 were due to 7-valent vaccine serotypes in 2001, compared with 24 cases, including 10 due to vaccine serotypes, in 2002. This represents a statistically significant increase in the proportion of total isolates due to non-vaccine serotypes (c 2 = 3.93, p = 0.048) following the introduction of the 7-valent conjugate vaccine, principally due to serotypes 7F and 12F. The number of episodes due to penicillin resistant isolates decreased from nine in 2001 to two in 2002. Ninety per cent of isolates from Indigenous adults were included in the 23-valent polysaccharide vaccine and six per cent and five per cent had reduced susceptibility to penicillin and erythromycin, respectively. Conjugate pneumococcal vaccines can be expected to reduce the incidence of IPD due to vaccine serotypes in vaccinated children and potentially, their adult contacts. It may also impact favourably on the incidence of IPD due to penicillin and erythromycin resistant strains. Continued surveillance of both serotype distribution and antibiotic susceptibility are required to identify serotype replacement by non-vaccine serotypes and to monitor the overall impact of current and future vaccine programs on invasive pneumococcal disease in Australia. Commun Dis Intell 2003;27:478-487.

Downloads

Download data is not yet available.

References

Kertesz DA, Di Fabio JL, de Cunto Brandileone MC, Castaneda E, Echaniz-Aviles G, Heitmann I, et al. Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance Study. Clin Infect Dis 1998;26:1355-1361.

Jette LP, Lamothe F. Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol 1989;27:1-5.

Nielsen SV, Henrichsen J. Capsular types of Streptococcus pneumoniae isolated from blood and CSF during 1982-1987. Clin Infect Dis 1992;15:794-798.

Voss L, Lennon D, Okesene-Gafa K, Ameratunga S, Martin D. Invasive pneumococcal disease in a pediatric population, Auckland, New Zealand. Pediatr Infect Dis J 1994;13:873-878.

Zangwill KM, Vadheim CM, Vannier AM, Hemenway LS, Greenberg DP, Ward JI. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 1996;174:752-759.

McIntyre PB, Nolan TM. Conjugate pneumococcal vaccines for non-indigenous children in Australia. [Review]. Med J Aust 2000;173 Suppl:S54-S57.

McIntyre PB, Gilmour RE, Gilbert GL, Kakakios AM, Mellis CM. Epidemiology of invasive pneumococcal disease in urban New South Wales, 1997-1999. Med J Aust 2000;173 Suppl:S22-S26.

Krause VL, Reid SJ, Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994-1998. Med J Aust 2000;173 Suppl:S27-S31. Erratum in Med J Aust 2001;174:309.

Hogg GG, Strachan JE, Lester RA. Invasive pneumococcal disease in the population of Victoria. Med J Aust 2000;173 Suppl:S32-S35.

Vaccine Impact Surveillance Network. Are current recommendations for pneumococcal vaccination appropriate for Western Australia? Vaccine Impact Surveillance Network-Invasive Pneumococcal Study Group. Med J Aust 2000;173 Suppl:S36-S40.

Turnidge JD, Bell JM, Collignon PJ. Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Pneumococcal Study Group. Med J Aust 1999;170:152-155.

Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.[comment]. N Engl J Med 2003;348:1737-1746.

National Health and Medical Research Council. The Australian Immunisation Handbook, 8th edition. Canberra: Australian Government Publishing Service, 2003, p. 143-152.

Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21:810-815.

Downloads

Published

31/12/03

How to Cite

Watson, Michael, K Bayley, Jan M Bell, Gwendolyn L Gilbert, Geoff Hogg, Anthony D Keil, Vicki Krause, et al. 2003. “Laboratory Surveillance of Invasive Pneumococcal Disease in Australia in 2001 to 2002 - Implications for Vaccine Serotype Coverage”. Communicable Diseases Intelligence 27 (December):478-87. https://doi.org/10.33321/cdi.2003.27.76.

Issue

Vol. 27 (2003)

Section

Annual report

Categories

License

Copyright (c) 2003 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>